Get started
Author

Eleen Rothschedl

Observed names: E Rothschedl, E. Rothschedl, Rothschedl, Eleen
OpenAlex ID: A5022407386
Twelve years of European cancer drug approval—a systematic investigation of the ‘magnitude of clinical benefit’
2021 · N. Grössmann, S. Wolf, et al. · ESMO Open · 27
Publicly accessible evidence of health-related quality of life benefits associated with cancer drugs approved by the European Medicines Agency between 2009 and 2015
2020 · Nicole Grössmann, Martin Robausch, et al. · European Journal of Cancer · 13
Entry techniques in gynecologic laparoscopy—a review
2011 · Johannes Ott, Agnes Jaeger-Lansky, et al. · Gynecological Surgery · 12
Coronary Sinus Reducing Stent for the Treatment of Refractory Angina Pectoris: A Health Technology Assessment
2020 · Michal Stanak, Eleen Rothschedl, et al. · Medical Devices Evidence and Research · 1
PDF
Endometriosis: International Care Standards and Healthcare Reality in Vienna
2026 · Grabenhofer, Lena, Giess, Doris, et al.
Publicly accessible evidence of health related quality of life benefits associated with cancer drugs approved by the European Medicines Agency between 2009 and 2015
2020 · N Grössmann, M Robausch, et al. · Das Gesundheitswesen
Percutaneous Transvascular Implantation of a Coronary Sinus Reducing Stent
2020 · Michal Stanak, E. Rothschedl
Horizon Scanning in Oncology 41st Prioritisation – 4th quarter 2019
2019 · N. Grössmann, E. Rothschedl, et al.
Enzalutamide (Xtandi®) in addition to standard first-line therapy in men with metastatic hormone-sensitive prostate cancer (mHSPC)
2019 · E. Rothschedl
Horizon Scanning in Oncology 40th Prioritisation – 3rd quarter 2019
2019 · N. Grössmann, E. Rothschedl, et al.
Darolutamide for the treatment of patients with nonmetastatic castration-resistant prostate cancer (CRPC)
2019 · E. Rothschedl
Horizon Scanning in Oncology 39th Prioritisation – 2nd quarter 2019
2019 · N. Groessmann, E. Rothschedl, et al.
Olaparib (Lynparza®) as first-line maintenance therapy in patients with newly diagnosed advanced ovarian cancer
2019 · E. Rothschedl
Published Evidence of Health-Related Quality of Life Benefits Associated with Cancer Drugs Approved by the European Medicine Agency between 2009 and 2015
2019 · Nicole Groessmann, Martin Robausch, et al. · SSRN Electronic Journal
Enzalutamide (Xtandi®) in patients with nonmetastatic, castration-resistant prostate cancer (CRPC)
2018 · E. Rothschedl
Horizon Scanning in Oncology 37th Prioritization – 4th quarter 2018
2018 · N. Grössmann, E. Rothschedl, et al.
Nivolumab (Opdivo®) in combination with ipilimumab (Yervoy®) for the first-line treatment of patients with advanced RCC
2018 · E. Rothschedl
Daratumumab (Darzalex®) in combination with bortezomib, melphalan and prednisone for untreated myeloma
2018 · E. Rothschedl
Horizon Scanning in Oncology 36th Prioritisation – 3rd quarter 2018
2018 · N. Grössmann, E. Rothschedl, et al.
Horizon Scanning in Oncology 35th Prioritisation – 2nd quarter 2018
2018 · N. Grössmann, E. Rothschedl, et al.
Rituximab (MabThera®) after autologous stem-cell transplantation (ASCT) in mantle cell lymphoma (MCL)
2018 · E. Rothschedl
Horizon Scanning in Oncology 34th Prioritisation – 1st quarter 2018
2018 · N. Grössmann, S. Wolf, et al.
Bevacizumab (Avastin®) in addition to standard chemotherapy for the first-line treatment of ovarian cancer
2016 · E. Rothschedl, A. Nachtnebel
Pembrolizumab (Keytruda®) for the treatment of advanced melanoma
2015 · E. Rothschedl, A. Nachtnebel
Carfilzomib (Kyprolis®) for patients with relapsed multiple myeloma who have received one to three prior lines of therapy
2015 · E. Rothschedl, A. Nachtnebel
Works count: 37
Citation count: 53
H-index: 3
I10-index: 3
Year
Topic
Type